Protocols
12 protocol(s) meet the specified criteria
Disease Site: Multiple Myeloma
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
54767414MMY3021A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant.Not Open
A061202A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as part of first line therapy.Open
ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
EAA173CIRBDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM).Not Open
FADOI03-2016Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio StudyOpen
KCP-330-017STOMPKCP-330-017 STOMP A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple MyelomaOpen
LCCC1119A Multi-Center, Single-Arm, Phase II Study of Vorinostat (V) in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) Followed by VB Maintenance in Patients with Relapsed and Relapsed/Refractory Multiple MyelomaOpen
LCCC1603-ATLPhase I Study of the Administration of Autologous CAR-T Cells Targeting the CD138 Antigen for Relapsed / Refractory Multiple MyelomaOpen
LCCC1849PERMIT - PERsonalized BioMarkers for Immunotherapy TreatmentOpen
LCCC1851The STEPP Study: Sensors To Evaluate Physical PerformanceOpen
S1702-CIRBS1702, CIRB " A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for patients with previously treated Al AmyloidosisOpen